Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: A French adaptation of CARDS

Archives of Cardiovascular Diseases

Volumn 101, Issue 5, 2008, Pages 327-332

  Lafuma, Antione ^a   Colin, Xavier ^a   Solesse, Anne ^b  

^a CEMKA EVAL   (France)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG COST; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

EID: 49749088895     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.05.003     Document Type: Article

References (17)

1. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004 Jan;27(1):201-7.
2. Cothoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, et al. Collaborative AtoRvastatin Diabetes Study (CARDS). Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002 Mar; 19(3):201-11.
3. Thomason MJ, Colhoun HM, Livingstone SJ, Mackness MI, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabet Med 2004 Aug;21(8):901-5.
4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al., CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21;364(9435):685-96.
5. http://www.has-sante.fr/portail/display.jsp?id=c-400830.
6. Fernandez de Bobadilla J, Lopez de Sa E, Alonso Troncoso I, Moreno Gomez R, Rubio-Terres C, Soto Alvarez J. Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes meilitus: a pharmacoeconomic model of the CARDS study. An Med Interna 2006 May;23(5): 213-9.
7. Raikou M, McGuire A, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, et al. CARDS Investigators. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007 Apr;50(4):733-40.
8. Recommandations de bonnes pratiques des méthodes d'évatuation économique des stratégiques thérapeutiques. Journal d'Économie Médicale 1998, 16, 4-5, 329-352.
9. http://www.ces-asso.org.
10. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision - making. Am J Med 1982 Dec;73(6): 889-97.
11. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998 Jul;21(7):1138-45.
12. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, et al., UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no.68). Diabetologia 2004;47(10):1747-59.
13. Stevens R, Adler A, Gray A, Briggs A, Holman R. Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 2000 Nov;50(Suppl 3):S5-13.
14. http://www.ined.fr/population-en-chiffres/france/index.html: Table de mortatité, années 2000-2002 Mortalité générate. Mise à jour: 2004.
15. http://www.invs.sante.fr/publications/entred/pdf/ caracteristiques-hospitatisations.pdf. 2006.
16. Colin X, Lafuma A, Gueron B. Costs of cardiovascular events of diabetic patients in the French hospitals. Diabetes Metab 2007;33(4):310-3.
17. Indice des prix à la consommation par secteur conjoncturel: Services de santé, période 2003 à 2007. Institut national de la statistique et des études économiques - www.insee.fr.